US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have ...

Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of ...

Achilles Therapeutics has announced it will discontinue its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T ...

The UK’s MHRA has approved Takeda’s Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC) in adults who have not ...

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...

Leslie Orne, president and CEO of Trinity Life Sciences, emphasizes the importance of corporate efficiency in the highly ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

The US Food and Drug Administration yesterday approved a new indication for Rybrevant (amivantamab-vmjw), from Johnson & ...

Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...

Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...

Edgewise Therapeutics has reported positive top-line results for its HCM treatment candidate, EDG-7500, boosting shares by ...